Translational research and the predictive, diagnostic biomarkers are critical to oncology drug development and clinical practice. We see enormous potential in the use of companion diagnostics to help identify patients who are most likely to respond to a specific therapy.  As part of this effort, we are developing predictive biomarkers to guide targeted, personalized treatment options for different cancers. Co-development of drugs and diagnostics requires close collaboration between Translational Research and Diagnostic Development teams. The integration of our Oncology Translational Research and Oncology Diagnostic teams enables us to collaborate and align to quickly react and adapt to new discoveries from the clinic to accelerate the development of drugs and companion diagnostics.